Page 20 - Priority Review News Today

Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, ...

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...

Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis  Approval based on Phase 3 EoE KIDS trial showing a greater...

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...

UTILITY therapeutics Ltd. Announces Financing Led by the AMR Action ...

SHANGHAI - GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S. Food and Drug Administration has recently...

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — ...

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, announced that U.S....

(MENAFN - GlobeNewsWire - Nasdaq) - NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 - - NDA is supported by data from successful Phase ... ...